Related references
Note: Only part of the references are listed.Long-term safety and efficacy of imatinib mesylate (Gleevec (R)) in elderly patients with chronic phase chronic myelogenous leukemia: Results of the AFR04 study
Philippe Rousselot et al.
AMERICAN JOURNAL OF HEMATOLOGY (2013)
Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience
Hagop Kantarjian et al.
BLOOD (2012)
Racial disparities in hematopoietic cell transplantation in the United States
N. S. Majhail et al.
BONE MARROW TRANSPLANTATION (2012)
Cancer Statistics, 2012
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2012)
Considerations in the Management of Elderly Patients With Chronic Myeloid Leukemia
Karen Seiter
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2012)
Tyrosine kinase inhibitors for elderly chronic myeloid leukemia patients: A systematic review of efficacy and safety data
Massimo Breccia et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2012)
Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party
Gabriele Gugliotta et al.
BLOOD (2011)
Success Story of Targeted Therapy in Chronic Myeloid Leukemia: A Population-Based Study of Patients Diagnosed in Sweden From 1973 to 2008
Magnus Bjorkholm et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Survival of Patients with Chronic Myelocytic Leukemia: Comparisons of Estimates from Clinical Trial Settings and Population-Based Cancer Registries
Dianne Pulte et al.
ONCOLOGIST (2011)
Age Disparity in the Dissemination of Imatinib for Treating Chronic Myeloid Leukemia
Charles L. Wiggins et al.
AMERICAN JOURNAL OF MEDICINE (2010)
Real- life results of front-line treatment with Imatinib in older patients (≥65 years) with newly diagnosed chronic myelogenous leukemia
Roberto Latagliata et al.
LEUKEMIA RESEARCH (2010)
Race and Socioeconomic Status Influence Outcomes of Unrelated Donor Hematopoietic Cell Transplantation
K. Scott Baker et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2009)
Recent trends in long-term survival of patients with chronic myelocytic leukemia: disclosing the impact of advances in therapy on the population level
Hermann Brenner et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2008)
Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party
Gianantonio Rosti et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2007)
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
Brian J. Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Gender aspects in chronic myeloid leukemia:: long-term results from randomized studies
U Berger et al.
LEUKEMIA (2005)
Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia
J Cortes et al.
CANCER (2003)
Trends in leukemia incidence and survival in the United States (1973-1998)
Y Xie et al.
CANCER (2003)
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the philadelphia chromosome.
BJ Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Share Paper
